Recently, a phase I dose escalation/expansion study (NCT03260491) has reported a confirmed objective response rate of 39% and a median progression-free survival of 8.2 months for patients with locally advanced or metastatic EGFR-mutant NSCLC treated with patritumab deruxtecan (HER3-DXd; U3-1402), an ADC consisting of an IgG1-kappa HER3 monoclonal antibody combined with the topoisomerase I inhibitor deruxtecan, after prior failure of EGFR TKI therapy. This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.